632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301

B.Burtness; J.Manola; A.Argiris; D.Altieri; R.Axelrod; A.Forastiere

首页> 外文期刊>European Journal of Cancer Supplements >632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301

【24h】

632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301

机译：632 POSTER对患有转移性或复发性头颈部鳞状细胞癌的患者，每天X 5天或每周进行一次BMS-247550（NSC 710428）的随机II期研究：E2301

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2006年第12期|共2页
作者
B.Burtness; J.Manola; A.Argiris; D.Altieri; R.Axelrod; A.Forastiere;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
专利

1. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. [J] . Burtness BA, Manola J, Axelrod R, Annals of oncology: official journal of the European Society for Medical Oncology . 2008,第5期

机译：ixabepilone（BMS-247550）的II期随机研究，每3周或每周x 5天，每周3次或每周一次，用于转移性或复发性头颈部鳞状细胞癌患者：一项东部合作肿瘤小组研究。
2. A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study [J] . B. A. Burtness1 J. Manola2 R. Axelrod3 A. Argiris4 and A. A. Forastiere5 Annals of Oncology . 2008,第5期

机译：ixabepilone（BMS-247550）的II期随机研究，每3周或每周3次或每周5天，对转移性或复发性头颈部鳞状细胞癌患者进行研究：一项东部合作肿瘤小组研究
3. 1029 POSTER A phase II study of sorafenib (BAY 43–9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) [J] . European Journal of Cancer Supplements . 2005,第2期

机译：1029 POSTER索拉非尼（BAY 43–9006）在复发和/或转移性头颈部鳞状细胞癌（HNSCC）和鼻咽癌（NPC）患者中进行的II期临床研究
4. Survival prediction of squamous cell head and neck cancer patients based on radiomic features selected from lung cancer patients using artificial neural network [C] . H. Kamezawa, H. Arimura, M. Soufi SPIE Medical Imaging Conference . 2018

机译：利用人工神经网络从肺癌患者的放射学特征中预测鳞状细胞癌的生存率
5. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) [O] . L. A. Dunn, M. G. Fury, H. Xiao, -1

机译：替西罗莫司的II期研究与低剂量每周卡铂和紫杉醇联合治疗复发和/或转移性（R / M）头颈部鳞状细胞癌（HNSCC）患者
6. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group Study [O] . Schornagel J.H., Verweij J., Mulder P.H.M. de, 1995

机译：乙草胺酯与甲氨蝶呤在头颈部转移性和/或复发性鳞状细胞癌患者中的III期随机试验：欧洲癌症头颈部癌研究与治疗组织合作研究

632 POSTER Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301

著录项

引文网络

相似文献

相关主题

期刊订阅